PD-LOOP study

  • Research type

    Research Study

  • Full title

    Early identification of Pre-diabetes and evaluation of Lifestyle Therapy in Children and Adolescents with Obesity using Continuous Glucose Monitoring System

  • IRAS ID

    304419

  • Contact name

    Senthil Senniappan

  • Contact email

    Senthil.Senniappan@alderhey.nhs.uk

  • Sponsor organisation

    Alder Hey Children's Hospital

  • Duration of Study in the UK

    1 years, 0 months, 11 days

  • Research summary

    Background:
    Childhood obesity is a worldwide public health concern with rates continuing to rise. Obesity has a huge impact on an individual’s overall health and wellbeing, due to complications such as type 2 diabetes mellitus (T2DM). T2DM is a widely recognised condition in the adult population, but sadly this issue is increasingly common in childhood and has its own serious complications. The association between childhood obesity and progression to T2DM is both a medical and public health concern.

    Aim:
    The aim of our project is to investigate glucose variation using continuous glucose monitoring (CGM) devices in children and young people with obesity.

    Why?
    Pre-diabetes is an under-recognised condition, which is diagnosed when glucose levels are above the normal range, but not high enough for a formal diagnosis of T2DM. It is a known predictor for developing T2DM. Therefore, if glucose dysregulation can be identified earlier and lifestyle modifications are beneficial, it may prevent commencing medications and requiring long-term treatment.

    Design:
    This is a pilot study at one tertiary paediatric hospital to gather preliminary data and show the feasibility of conducting a full-scale trial. 50 participants aged 8-18 years, body mass index >98th percentile, recent oral glucose tolerance test (OGTT), and do not meet the exclusion criteria will be considered.
    Participants will be asked to attend the site for baseline fasting bloods, measurements, and completion of questionnaires. A CGM and ActivPal will be inserted for 10 days to obtain free-living data. The participant will then commence a 12-week lifestyle intervention, with two weekly reviews. They will return to the site post-intervention for repeat bloods, OGTT, measurements and questionnaires. The CGM and ActivPal will be inserted again for a further 10 days.
    Comparison between fasting bloods, biomarkers, measurements, questionnaires, OGTT, CGM and ActivPal results pre- and post-intervention will be analysed.

  • REC name

    North East - Newcastle & North Tyneside 1 Research Ethics Committee

  • REC reference

    21/NE/0235

  • Date of REC Opinion

    19 Jan 2022

  • REC opinion

    Further Information Favourable Opinion